Scott Rottinghaus
Chief Tech/Sci/R&D Officer presso ENANTA PHARMACEUTICALS, INC.
Patrimonio netto: 493 891 $ in data 31/03/2024
Profilo
Scott T.
Rottinghaus is currently the Chief Medical Officer & Senior Vice President at Enanta Pharmaceuticals, Inc. Previously, he worked as the Vice President & Head-Clinical Development at Alexion Pharmaceuticals, Inc. He received his doctorate from Mayo Medical School, his graduate degree from the University of Cambridge, and his undergraduate degree from Kansas State University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 12/02/2024 | 28 287 ( 0.13% ) | 493 891 $ | 31/03/2024 |
Posizioni attive di Scott Rottinghaus
| Società | Posizione | Inizio |
|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 08/08/2022 |
Precedenti posizioni note di Scott Rottinghaus
| Società | Posizione | Fine |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formazione di Scott Rottinghaus
| University of Cambridge | Graduate Degree |
| Kansas State University | Undergraduate Degree |
| Mayo Medical School | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Scott Rottinghaus
